Graham Clarke, CEO of ImmBio comments: "Having established proof of principle of the broad-based utility of the technology platform, this funding will enable ImmBio to progress its candidates into pre-clinical development.
The technology platform (HspC) is based on Heat Shock Protein Complexes (HspCs), which play the pivotal role of bridging between the innate and adaptive immunological response. The approach is expected to result in products with a broader, faster and safer profile compared with existing and new vaccines.
The work on Influenza includes studies of protection against major strain change, the current concern with avian ‘flu. ImmBio’s candidates have demonstrated protection, providing a robust basis for polyclonal immunity, required to address both gradual strain drift and strain shift. There is now widespread recognition of the risk posed from strain shift, potentially leading to global pandemic, due to lack of immunity." |
